Christensen Michelle B, Langhorn Rebecca, Goddard Amelia, Andreasen Eva B, Moldal Elena, Tvarijonaviciute Asta, Kirpenteijn Jolle, Jakobsen Sabrina, Persson Frida, Kjelgaard-Hansen Mads
Department of Veterinary Clinical and Animal Sciences, University of Copenhagen, 3 Groennegaardsvej, Frederiksberg C, Denmark.
J Vet Med Sci. 2013 May 2;75(4):459-66. doi: 10.1292/jvms.12-0404. Epub 2012 Nov 28.
Canine serum amyloid A (SAA) is a useful diagnostic marker of systemic inflammation. A latex agglutination turbidimetric immunoassay (LAT) was validated for automated measurements. The aim of the study was to evaluate the clinical applicability of SAA measured by the LAT. SAA was measured in 7 groups of dogs with and without systemic inflammation (n=247). Overlap performance was investigated. Diagnostic performance was compared to body temperature and leukocyte markers. Clinical decision limits for SAA were estimated. In dogs with neurological, neoplastic or gastrointestinal disorders (n=143), it was investigated whether a higher proportion of SAA positive dogs could be detected in cases of complications with risk of systemic inflammation. Significantly higher concentrations of SAA were measured in dogs with (range [48.75; 5,032 mg/l]), compared to dogs without systemic inflammation [0; 56.4 mg/l]. SAA was a more sensitive and specific marker of systemic inflammation (area under the receiver-operating characteristic curve (AUC) 1.00), compared to body temperature (0.6) and segmented neutrophils (best performing leukocyte marker, 0.84). A clinical decision limit of 56.4 mg/l was established giving close to perfect discrimination between dogs with and without systemic inflammation. Higher proportions of SAA-positive dogs were observed in dogs with neurological, neoplastic and gastrointestinal disorders with complications known to increase risk of systemic inflammation, compared to uncomplicated cases. The automated LAT makes SAA applicable as a relevant diagnostic marker of systemic inflammation in dogs for routine random-access real-time use in a general clinical setting.
犬血清淀粉样蛋白A（SAA）是全身性炎症的一种有用诊断标志物。一种乳胶凝集比浊免疫测定法（LAT）已被验证可用于自动测量。本研究的目的是评估通过LAT测量的SAA的临床适用性。在7组有或无全身性炎症的犬中测量了SAA（n = 247）。研究了重叠性能。将诊断性能与体温和白细胞标志物进行了比较。估计了SAA的临床决策限。在患有神经、肿瘤或胃肠道疾病的犬（n = 143）中，研究了在有全身性炎症风险的并发症病例中是否能检测到更高比例的SAA阳性犬。与无全身性炎症的犬[0；56.4 mg/l]相比，患有全身性炎症的犬（范围[48.75；5,032 mg/l]）中测量到的SAA浓度显著更高。与体温（0.6）和分叶中性粒细胞（表现最佳的白细胞标志物，0.84）相比，SAA是全身性炎症更敏感和特异的标志物（受试者操作特征曲线下面积（AUC）为1.00）。确定了56.4 mg/l的临床决策限，能近乎完美地区分有和无全身性炎症的犬。与无并发症的病例相比，在患有神经、肿瘤和胃肠道疾病且已知并发症会增加全身性炎症风险的犬中，观察到更高比例的SAA阳性犬。自动化LAT使SAA适用于作为犬全身性炎症的相关诊断标志物，在一般临床环境中进行常规随机即时实时使用。
